Background
Methods
Patient characteristics
p16 | n | age mean | SD | range | |
---|---|---|---|---|---|
VIN
| pos | 93 | 49.1 | ± 14.6 | 22 - 89 |
Neg | 13 | 74.3 | ± 14.9 | 35 - 93 | |
VSCC
| Pos | 31 | 61.8 | ± 14.3 | 37 - 90 |
Neg | 26 | 77.3 | ± 10.3 | 53 - 93 |
n | percentage | |
---|---|---|
T stage
| ||
1 | 22 | 37.3% |
2 | 24 | 40.7% |
3 | 9 | 15.3% |
4 | 0 | 0.0% |
Not available | 4 | 6.8% |
Lymphe node metasases
| ||
None | 24 | 40.7% |
Unilateral | 14 | 23.7% |
Bilateral | 6 | 10.2% |
Not available | 15 | 25.4% |
Distant metastases
| ||
No | 28 | 47.5% |
Yes | 1 | 1.7% |
Not available | 30 | 50.8% |
FIGO
| ||
I | 16 | 27.1% |
II | 12 | 20.3% |
III | 13 | 22.1% |
IV | 5 | 9.5% |
Not available | 13 | 22.0% |
Tumor differentiation
| ||
Well | 13 | 22.0% |
Moderate | 30 | 50.8% |
Poor | 16 | 27.1% |
Tissue Microarray construction
Immunohistochemistry
Results
HDAC expression in VIN and VSCC
Total | HDAC1 low | HDAC1 high | p | HDAC2 low | HDAC2 high | p | HDAC3 low | HDAC3 high | p | |
---|---|---|---|---|---|---|---|---|---|---|
All Cases
| 163 | 70 (42.9%) | 93 (57.1%) | -- | 38 (23.3%) | 125 (76.7%) | -- | 32 (19.6%) | 131 (80.4%) | -- |
VIN
| 106 | 45 (42.5%) | 61 (57.5%) | 0.87 | 12 (11.3%) | 94 (88.7%) |
< 0.001
| 28 (26.4%) | 78 (73.6%) |
0.003
|
VSCC
| 57 | 25 (43.9% | 32 (56.1%) | 26 (45.6%) | 31 (54.4%) | 4 (7.0%) | 53 (93.0%) | |||
p16 neg
| 39 | 17 (43.6%) | 22 (56.4%) | 1.00 | 10 (25.6%) | 29 (74.4%) | 0.67 | 4 (10.3%) | 35 (89.7%) | 0.109 |
p16 pos
| 124 | 53 (42.7%) | 71 (57.3%) | 28 (22.6%) | 96 (77.4%) | 28 (22.6%) | 96 (77.4%) | |||
Age ≤ 60
| 93 | 41 (44.1%) | 52 (55.9%) | 0.752 | 22 (23.7%) | 71 (76.3%) | 1.00 | 21 (22.6%) | 72 (77.4%) | 0.322 |
Age > 60
| 70 | 29 (41.4%) | 41 (58.6%) | 16 (22.9%) | 54 (77.1%) | 11 (15.7%) | 59 (84.3%) | |||
VSCC°
| ||||||||||
pT1
| 20 | 7 (35.0%) | 13 (65.0%) | 0.556* | 5 (25.0%) | 15 (75.0%) | 0.057* | 1 (5.0%) | 19 (95.0%) | 0.831* |
pT2
| 24 | 11 (45.8%) | 13 (54.2%) | 13 (54.2%) | 11 (45.8%) | 2 (8.3%) | 22 (91.7%) | |||
pT3
| 9 | 5 (55.6%) | 4 (44.4%) | 6 (66.7%) | 3 (33.3%) | 1 (11.1%) | 8 (88.9%) | |||
pN0
| 23 | 9 (39.1%) | 14 (60.9%) | 0.763 | 9 (39.1%) | 14 (60.9%) | 0.366 | 1 (4.3%) | 22 (95.7%) | 1.00 |
pN1/2
| 20 | 9 (45.0%) | 11 (55.0%) | 11 (55.0%) | 9 (45.0%) | 1 (5.0%) | 19 (95.0%) | |||
G1
| 12 | 5 (41.7%) | 7 (58.3%) |
0.009*
| 7 (58.3%) | 5 (41.7%) | 0.602* | 1 (8.3%) | 11 (91.7%) | 0.513* |
G2
| 29 | 8 (27.6%) | 21 (72.4%) | 12 (41.4%) | 17 (58.6%) | 1 (3.4%) | 28 (96.6%) | |||
G3
| 16 | 12 (75%) | 4 (25.0%) | 7 (43.8%) | 9 (56.3%) | 2 (12.5%) | 14 (87.5%) | |||
VIN
| ||||||||||
Ki-67 ≤ 10%
| 11 | 9 (81%) | 2 (18.2%) |
0.008
| 3 (27.3%) | 8 (72.7%) | 0.109 | 4 (36.4%) | 7 (63.6%) | 0.476 |
Ki-67 > 10%
| 95 | 36 (37.9%) | 59 (62.1%) | 9 (9.5%) | 86 (90.5%) | 24 (25.3%) | 71 (74.7%) | |||
VSCC
| ||||||||||
Ki-67 ≤ 10%
| 19 | 8 (42.1%) | 11 (57.9%) | 1.00 | 14 (73.7%) | 5 (26.3%) |
0.004
| 2 (10.5%) | 17 (89.5%) | 0.594 |
Ki-67 > 10%
| 38 | 17 (44.7%) | 21 (55.3%) | 12 (31.6%) | 26 (68.4%) | 2 (5.3%) | 36 (94.7%) |